UY32318A - Combinación antitumoral que asocia ave8062 y docetaxel - Google Patents

Combinación antitumoral que asocia ave8062 y docetaxel

Info

Publication number
UY32318A
UY32318A UY0001032318A UY32318A UY32318A UY 32318 A UY32318 A UY 32318A UY 0001032318 A UY0001032318 A UY 0001032318A UY 32318 A UY32318 A UY 32318A UY 32318 A UY32318 A UY 32318A
Authority
UY
Uruguay
Prior art keywords
ave8062
docetaxel
associates
antitumoral combination
antitumoral
Prior art date
Application number
UY0001032318A
Other languages
English (en)
Inventor
Besenval Michele
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32318A publication Critical patent/UY32318A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una combinación antitumoral y secuencial de AVE8062 o de una sal de AVE8062 y de docetaxel caracterizada porque VE8062 se administra a un paciente a una dosis comprendida entre 10 y 50 mg/m2 y un día diferente de la semana, preferentemente después de un intervalo de 24 horas, el docetaxel a una dosis comprendida entre 50 y 120 mg/m2.
UY0001032318A 2008-12-12 2009-12-11 Combinación antitumoral que asocia ave8062 y docetaxel UY32318A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0806979A FR2939665B1 (fr) 2008-12-12 2008-12-12 Combinaison antitumorale associant l'ave8062a et le docetaxel

Publications (1)

Publication Number Publication Date
UY32318A true UY32318A (es) 2010-07-30

Family

ID=40790630

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032318A UY32318A (es) 2008-12-12 2009-12-11 Combinación antitumoral que asocia ave8062 y docetaxel

Country Status (27)

Country Link
US (1) US20120004294A1 (es)
EP (1) EP2376076A1 (es)
JP (1) JP2012511554A (es)
KR (1) KR20110104932A (es)
CN (1) CN102245175A (es)
AR (1) AR074599A1 (es)
AU (1) AU2009326220A1 (es)
BR (1) BRPI0923349A2 (es)
CA (1) CA2746475A1 (es)
CL (1) CL2011001316A1 (es)
CO (1) CO6390037A2 (es)
CR (1) CR20110319A (es)
EA (1) EA201170803A1 (es)
EC (1) ECSP11011112A (es)
FR (1) FR2939665B1 (es)
IL (1) IL213458A0 (es)
MA (1) MA32955B1 (es)
MX (1) MX2011006253A (es)
NI (1) NI201100114A (es)
PA (1) PA8853301A1 (es)
PE (1) PE20120125A1 (es)
SG (1) SG172071A1 (es)
TN (1) TN2011000268A1 (es)
TW (1) TW201032798A (es)
UY (1) UY32318A (es)
WO (1) WO2010067027A1 (es)
ZA (1) ZA201104358B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
AU2002246827B2 (en) 2000-12-22 2008-02-21 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20050209310A1 (en) 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines

Also Published As

Publication number Publication date
KR20110104932A (ko) 2011-09-23
CO6390037A2 (es) 2012-02-29
ZA201104358B (en) 2012-09-26
US20120004294A1 (en) 2012-01-05
MX2011006253A (es) 2011-11-04
EA201170803A1 (ru) 2011-12-30
AR074599A1 (es) 2011-01-26
BRPI0923349A2 (pt) 2015-07-21
WO2010067027A1 (fr) 2010-06-17
SG172071A1 (en) 2011-07-28
TN2011000268A1 (fr) 2012-12-17
PE20120125A1 (es) 2012-02-23
CL2011001316A1 (es) 2011-10-28
ECSP11011112A (es) 2011-07-29
CR20110319A (es) 2011-09-20
MA32955B1 (fr) 2012-01-02
FR2939665A1 (fr) 2010-06-18
CA2746475A1 (fr) 2010-06-17
TW201032798A (en) 2010-09-16
IL213458A0 (en) 2011-07-31
NI201100114A (es) 2011-12-13
EP2376076A1 (fr) 2011-10-19
FR2939665B1 (fr) 2011-10-07
JP2012511554A (ja) 2012-05-24
AU2009326220A1 (en) 2011-07-07
CN102245175A (zh) 2011-11-16
PA8853301A1 (es) 2010-07-27

Similar Documents

Publication Publication Date Title
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
AR072516A1 (es) Metodos, sistemas y dispositivos para la administracion de dioxido de cloro a un tejido
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
PE20061051A1 (es) Composicion farmaceutica que comprende mirtazapina s
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
GT200800208A (es) Composición farmacèutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia.
UY32318A (es) Combinación antitumoral que asocia ave8062 y docetaxel
AR077846A1 (es) Metodo para disminuir los sintomas nasales asociado a la administracion de nicotina en la mucosa nasal
UA59011U (ru) Способ повышения эффективности протезирования у пациентов с нарушением гомеостаза ротовой полости
CY1120970T1 (el) Φαρμακευτικη μορφη δοσολογιας που περιλαμβανει 6'-φθορο-(ν-μεθυλ-ή ν,ν-διμεθυλ-)-4-φαινυλ-4',9'-διυδρο-3ή-σπeipo[kykλoeξano-1,1'-πυρano[3,4,b]inδoλ]-4-aminh για την αγωγη του αλγαισθητικου πονου
RU2008102726A (ru) Способ анестезии

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140808